We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 674.00 | 5.94% | 12,026.00 | 12,006.00 | 12,012.00 | 12,096.00 | 11,850.00 | 11,890.00 | 4,650,557 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.26 | 186.15B |
From Apr 2019 to Apr 2024
GlaxoSmithKline (GSK.LN) a annoncé jeudi que le président de sa division Global Pharmaceuticals, Abbas Hussain, quitterait le laboratoire pharmaceutique britannique courant 2017, après huit années passées au sein du groupe.
Il sera remplacé par Luke Miels, dont la date d'entrée en fonction sera annoncée en temps voulu, a indiqué GlaxoSmithKline.
Luke Miels est actuellement vice-président exécutif de l'activité européenne d'AstraZeneca (AZN).
-Ian Walker, Dow Jones Newswires (Version française Aurélie Henri) ed: ECH
(END) Dow Jones Newswires
January 19, 2017 04:15 ET (09:15 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
